Notice of Change to PAR-22-113, “Urgent Award: COVID-19 Mental Health Research (R01 Clinical Trial Optional)”
Notice Number:
NOT-MH-22-301

Key Dates

Release Date:

August 30, 2022

Related Announcements

 PAR-22-113 - Urgent Award: COVID-19 Mental Health Research (R01 Clinical Trial Optional)

Issued by

National Institute of Mental Health (NIMH)

Purpose

The purpose of this Notice is to alert potential applicants of the following change to PAR-22-113 “Urgent Award: COVID-19 Mental Health Research (R01 Clinical Trial Optional).” The changes in the PAR updated the areas of high priority for HIV/AIDS Research. Applications submitted to this Funding Opportunity Announcement must aim to address urgent, time-sensitive mental health research questions related to COVID-19, including broader secondary impacts of the pandemic as well as research on the intersection of mental health, COVID-19, and HIV.

Section I. Funding Opportunity Description of PAR-22-113 has been modified as follows:

Currently reads:

Areas of High Program Priority

HIV/AIDS Research

  • Use of statistical, mathematical, or computational approaches to enhance understanding and identify modifiable targets of provider, clinic and systems-level factors that may impact capacity to implement integrated COVID-19 screening with evidence-based screening for mental health and provision of appropriate mental health services among persons at high risk for HIV or people living with HIV.
  • Use of modeling approaches to examine and predict the impact of mental health and mental health comorbidities, stigma, and other social determinants of health on HIV-related outcomes in the context of the COVID-19 pandemic and strategies to mitigate the negative effects.
  • Epidemiologic and clinical studies of the incidence and prevalence of Post-Acute Sequelae of COVID-19 (PASC) in people living with HIV compared to participants without HIV with a focus on mental health, neurologic, and behavioral sequelae and relating to potentially modifiable immunologic, viral and treatment factors as well as other factors both during the SARS-CoV-2 infection and post-acute stages.
  • Research to understand the pathophysiology of acute and post-acute SARS-CoV-2 CNS complications in people living with HIV, including the role of immune dysfunction on neuronal function and reactivation of HIV from latent reservoirs.
  • Research that leverages existing cohorts to examine CNS complications including mental illness risk, onset, course as well as behavioral consequences due to SARS-CoV-2 immune responses and impact of SARS-CoV-2 co-infection with HIV on the CNS.
  • Research to understand whether and how the COVID-19 pandemic and associated restrictions may have affected HIV care engagement, medication adherence, and viral suppression among people living with HIV in a manner that would directly inform future support interventions, care continuity, and pandemic preparedness.
  • Research to understand the intersection of the COVID-19 pandemic, violence, mental health, and HIV prevention and treatment outcomes.

Modified to Read:

Areas of High Program Priority

HIV/AIDS Research

  • Use of statistical, mathematical, or computational approaches to enhance understanding and identify modifiable targets of provider, clinic and systems-level factors that may impact capacity to implement integrated COVID-19 screening with evidence-based screening for mental health and provision of appropriate mental health services among persons at high risk for HIV or people living with HIV.
  • Use of modeling approaches to examine and predict the impact of mental health and mental health comorbidities, stigma, and other social determinants of health on HIV-related outcomes in the context of the COVID-19 pandemic and strategies to mitigate the negative effects.
  • Epidemiologic and clinical studies of the incidence and prevalence of Post-Acute Sequelae of COVID-19 (PASC) in people living with HIV compared to participants without HIV with a focus on mental health and behavioral sequelae and relating to potentially modifiable immunologic, viral and treatment factors as well as other factors both during the SARS-CoV-2 infection and post-acute stages.
  • Research to understand the intersection of the COVID-19 pandemic, violence, mental health, and HIV prevention and treatment outcomes.

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Division of AIDS Research

Pim Brouwers, Ph.D.
National Institute of Mental Health (NIMH)
Telephone: 240-627-3863
Email:ebrouwer@mail.nih.gov

Division of Neuroscience and Basic Behavioral Science

Susan Koester, Ph.D.
National Institute of Mental Health (NIMH)
Telephone: 301-443-3563
Email:koesters@mail.nih.gov

Division of Services and Intervention Research

Adam Haim, Ph.D.
National Institute of Mental Health (NIMH)
Telephone: 301-435-3593
Email:Haima@mail.nih.gov

Division of Translational Research

Susan Borja, Ph.D.
National Institute of Mental Health (NIMH)
Telephone: 301-443-1252
Email:susan.borja@nih.gov

Center for Global Mental Health Research

Leonardo Cubillos, M.D. M.Ph.
National Institute of Mental Health (NIMH)
Telephone: 301-827-9095
Email:Leonardo.cubillos@nih.gov

Office for Disparities Research and Workforce Diversity (ODWD)

Dawn Morales Ph.D.
National Institutes of Mental Health (NIMH)
Telephone: 301-827-9668
Email:dawn.morales@nih.gov